Neuroprotective properties of mildronate, a mitochondria-targeted small molecule

Neuroscience Letters

Volumn 470, Issue 2, 2010, Pages 100-105

  Pupure, Jolanta ^a   Isajevs, Sergejs ^a   Skapare, Elina ^b   Rumaks, Juris ^a   Svirskis, Simons ^a   Svirina, Darja ^a   Kalvinsh, Ivars ^b   Klusa, Vija ^a  

^a UNIVERSITY OF LATVIA   (Latvia)

^b LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

Author keywords

Azidothymidine neurotoxicity; Mildronate; Neurodegeneration; Neuroinflammation; Neuroprotection

Indexed keywords

CASPASE 3; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; CYTOCHROME C OXIDASE; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MILDRONATE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN TISSUE; CELL INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; IMMUNOHISTOCHEMISTRY; MALE; MITOCHONDRION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; WESTERN BLOTTING;

ANIMALS; ANTI-HIV AGENTS; BRAIN; CASPASE 3; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX IV; GLIAL FIBRILLARY ACIDIC PROTEIN; LYMPHOCYTES; MALE; METHYLHYDRAZINES; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NITRIC OXIDE SYNTHASE TYPE II; ZIDOVUDINE;

EID: 74449088431     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.12.055     Document Type: Article

References (18)

1. Akahira M., Hara A., and Abiko Y. Effect of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on myocardial derangements induced by hydrogen peroxide in the isolated perfused rat heart. Fundam. Clin. Pharmacol. 11 (1997) 356-364
2. Allen N.J., and Barres B.A. Glia-more than just brain glue. Nature 457 (2009) 675-677
3. Brinkmann U., Brinkmann E., Gallo M., Scherf U., and Pastan I. Role of CAS, a human homologue to the yeast chromosome segregation gene CSE1, in toxin and TNF-mediated apoptosis. Biochemistry 35 (1996) 6891-6899
4. Dambrova M., Liepinsh E., and Kalvinsh I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc. Med. 12 (2002) 275-279
5. DeLegge M.H., and Smoke A. Neurodegeneration and inflammation. Nutr. Clin. Pract. 23 (2008) 35-41
6. Di Stefano A., Caramori G., Oates T., Capelli A., Lusuardi M., Gnemmi I., Ioli F., Chung K.F., Donner C.F., Barnes P.J., and Adcock I.M. Increased expression of nuclear factor-κB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 20 (2002) 556-563
7. Gown A.M., and Willingham M.C. Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J. Histochem. Cytochem. 50 (2002) 449-454
8. Granata S., Zaza G., Simone S., Villani G., Latorre D., Pontrelli P., Carella M., Schena F.P., Grandaliano G., and Pertosa G. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genom. 10 (2009) 388
9. Grigat S., Fork C., Bach M., Golz S., Geerts A., Schoming E., and Grundemann D. The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate. Drug Metab. Dispos. 37 (2009) 330-337
10. Hanaki Y., Sugiyama S., and Ozawa T. Effect of 3-(2,2,2-trimethylhydrazinium) propionate, gamma-butyrobetaine hydroxylase inhibitor, on isoproterenol-induced mitochondrial dysfunction. Res. Commun. Chem. Pathol. Pharmacol. 64 (1989) 157-160
11. Klusa V., Pupure J., Isajevs S., Rumaks J., Gordjushina V., Kratovska A., Taivans I., Svirskis S., Viksna L., and Kalvinsh I. Protection of azidothymidine-induced cardiopathology in mice by mildronate, a mitochondria-targeted drug. Basic Clin. Pharmacol. Toxicol. 99 (2006) 323-328
12. Liepinsh E., Vilskersts R., Skapare E., Svalbe B., Kuka J., Cirule H., Pugovics O., Kalvinsh I., and Dambrova M. Mildronate decreases carnitine availability and up-regulates glucose uptake and related gene expression in the mouse heart. Life Sci. 83 (2008) 613-619
13. May L.T., Leach K., Sexton P.M., and Christopoulos A. Allosteric modulation of G protein-coupled receptors. Ann. Rev. Pharmacol. Toxicol. 47 (2007) 1-51
14. Miecz D., Januszewicz E., Czeredys M., Hinton B.T., Berezowski V., Cecchelli R., and Nałecz K.A. Localization of organic cation/carnitine transporter (OCTN2) in cells forming the blood-brain barrier. J. Neurochem. 104 (2008) 113-123
15. Munhoz C.D., Garcia-Bueno B., Madriga J.L., Lepsch L.B., Scavone C., and Leza J.C. Stress-induced neuroinflammation: mechanisms and new pharmacological targets. Braz. J. Med. Biol. Res. 41 (2008) 1037-1046
16. Pupure J., Fernandes M.A.S., Santos M.S., Moreno A.J.M., Kalvinsh I., Klusa V., and Oliveira C.R. Mitochondria as the target for mildronate's protective effects in azidothymidine (AZT)-induced toxicity of isolated rat liver mitochondria. Cell Biochem. Funct. 26 (2008) 620-631
17. Wallace D.C. Mitochondrial diseases in man and mouse. Science 283 (1999) 1482-1488
18. Wang J.Y., Wen L.L., Huang Y.N., Chen Y.T., and Ku M.C. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated inflammation. Curr. Pharm. Des. 12 (2006) 3521-3533